Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Subbiah, Vivek ^a   Westin, Shannon N ^a   Wang, Kai ^b   Araujo, Dejka ^a   Wang, Wei Lien ^a   Miller, Vincent A ^b   Ross, Jeffrey S ^b,c   Stephens, Phillip J ^b   Palmer, Gary A ^b   Ali, Siraj M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOUNDATION MEDICINE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; BRAF; KIAA1549 BRAF; mTOR; N = 1 trial; Next generation sequencing; Sarcoma; Sorafenib; Spindle cell neoplasm; Targeted therapy

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CD34 ANTIGEN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HYBRID PROTEIN; IFOSFAMIDE; KIAA1549 BRAF FUSION PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S 100; RAF PROTEIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER PATIENT; CASE REPORT; DIAGNOSTIC KIT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUSION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL (TOPIC); SEQUENCE ANALYSIS; SPINDLE CELL CARCINOMA; SPINDLE CELL SARCOMA; STANDARD; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; ONCOGENE PROTEINS, FUSION; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; S100 PROTEINS; SARCOMA; SEQUENCE ANALYSIS, DNA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84892379425     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-8     Document Type: Article

References (20)

1. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Trojani MCG, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C, Int J Cancer 1984 33 37 42 10.1002/ijc.2910330108 6693192 (Pubitemid 14223231)
2. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. Westin S, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Simberidou AMT, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, Lu KH, Coleman RL, Kurzrock R, J Clin Oncol 2013. ASCO Annual Meeting Abstracts 2013 suppl; abstr 2611. 31 15 2611
3. BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors. Dimitriadis E, Alexiou GA, Tsotsou P, Simeonidi E, Stefanaki K, Patereli A, Prodromou N, Pandis N, J Neurooncol 2013 113 3 353 358 10.1007/s11060-013- 1131-5 23612919
4. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Serrano C, Simonetti S, Hernandez-Losa J, Valverde C, Carrato C, Bague S, Orellana R, Somoza R, Moline T, Carles J, et al. Histopathology 2013 62 3 499 504 10.1111/his.12021 23190154
5. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DTW, et al. J Clin Invest 2011 121 4 1344 1348 10.1172/JCI44656 21403401
6. Pharmacogenomics knowledge for personalized medicine. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE, Clin Pharmacol Ther 2012 92 4 414 417 10.1038/clpt.2012.96 22992668
7. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, et al. Pigment Cell Melanoma Res 2013 26 6 845 851 10.1111/pcmr.12148 23890088
8. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, et al. Nat Med 2010 16 7 793 798 10.1038/nm.2166 20526349
9. Ot-02. phase ii study of sorafenib in children with recurrent/progressive low-grade astrocytomas. Karajannis M, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, Harter DH, Hartnett E, Merkelson A, Bloom MC, Dhall G, Jones D, Korshunov A, Pfister S, Eberhart CG, Zagzag D, Allen JC, Neuro Oncol 2012 14 suppl 6 22i101 vi105
10. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, et al. Clin Cancer Res 2013 19 3 657 667 10.1158/1078-0432.CCR-11-1446 23251002
11. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R, Oncotarget 2013 4 2 310 315 23470635
12. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simoes M, Soares P, J Clin Endocrinol Metab 2012 97 7 1139 E1149 10.1210/jc.2011-2748 22549934
13. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, et al. Clin Cancer Res 2013 19 10 2688 2698 10.1158/1078-0432.CCR-12-2556 23549875
14. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, et al. Cancer Res 2012 72 18 4765 4776 10.1158/0008-5472.CAN-12-0820 22836754
15. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM, Mol Cancer Ther 2012 11 4 909 920 10.1158/1535-7163.MCT-11-0989 22389471
16. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al. PloS One 2011 6 12 28973 10.1371/journal.pone.0028973 22194965
17. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R, PloS One 2011 6 4 18424 10.1371/journal.pone.0018424 21494688
18. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Kaul A, Chen YH, Emnett RJ, Dahiya S, Gutmann DH, Genes Dev 2012 26 23 2561 2566 10.1101/gad.200907.112 23152448
19. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Jain RK, Science 2005 307 5706 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
20. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC, Proc Natl Acad Sci 2013 110 15 5957 5962 10.1073/pnas.1219232110 23533272